Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):349–350. doi: 10.1128/aac.28.2.349

Norfloxacin penetration into human renal and prostatic tissues.

M G Bergeron, M Thabet, R Roy, C Lessard, P Foucault
PMCID: PMC180245  PMID: 3834837

Abstract

Concurrent norfloxacin concentrations in serum, kidney, and prostatic tissue were determined in 14 patients. Mean ratios of norfloxacin concentration in tissue over concentration in serum were 6.6 +/- 2.8 for the kidney and 1.7 +/- 0.2 for the prostate samples. The levels were above the MICs of most urinary pathogens.

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adhami Z. N., Wise R., Weston D., Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother. 1984 Jan;13(1):87–92. doi: 10.1093/jac/13.1.87. [DOI] [PubMed] [Google Scholar]
  2. Bergeron M. G., Trottier S. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution. Antimicrob Agents Chemother. 1979 May;15(5):635–641. doi: 10.1128/aac.15.5.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bland J., Edison A., Huber J. Bioassay procedures for norfloxacin. Eur J Clin Microbiol. 1983 Jun;2(3):249–252. doi: 10.1007/BF02029527. [DOI] [PubMed] [Google Scholar]
  4. Fair W. R., Crane D. B., Schiller N., Heston W. D. A re-appraisal of treatment in chronic bacterial prostatitis. J Urol. 1979 Apr;121(4):437–441. doi: 10.1016/s0022-5347(17)56816-0. [DOI] [PubMed] [Google Scholar]
  5. Goldstein E. J., Alpert M. L., Ginsberg B. P. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):422–423. doi: 10.1128/aac.27.3.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Greenwood D., Osman M., Goodwin J., Cowlishaw W. A., Slack R. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance. J Antimicrob Chemother. 1984 Apr;13(4):315–323. doi: 10.1093/jac/13.4.315. [DOI] [PubMed] [Google Scholar]
  7. Neu H. C., Labthavikul P. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1982 Jul;22(1):23–27. doi: 10.1128/aac.22.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Norrby S. R., Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother. 1983 Jan;23(1):15–18. doi: 10.1128/aac.23.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Panichi G., Pantosti A., Testore G. P. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. J Antimicrob Chemother. 1983 Jun;11(6):589–592. doi: 10.1093/jac/11.6.589. [DOI] [PubMed] [Google Scholar]
  10. Sabbaj J., Hoagland V. L., Shih W. J. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):297–301. doi: 10.1128/aac.27.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Swanson B. N., Boppana V. K., Vlasses P. H., Rotmensch H. H., Ferguson R. K. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother. 1983 Feb;23(2):284–288. doi: 10.1128/aac.23.2.284. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES